Form 8-K - Current report:
SEC Accession No. 0001564590-20-016142
Filing Date
2020-04-09
Accepted
2020-04-09 17:01:41
Documents
13
Period of Report
2020-04-03
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20200403.htm   iXBRL 8-K 41664
2 EX-3.1 ntla-ex31_6.htm EX-3.1 4548
  Complete submission text file 0001564590-20-016142.txt   181413

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200403.xsd EX-101.SCH 5768
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200403_lab.xml EX-101.LAB 20226
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200403_pre.xml EX-101.PRE 12080
9 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20200403_htm.xml XML 3681
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 20785159
SIC: 2835 In Vitro & In Vivo Diagnostic Substances